Pseudomonas Infections

3

Review clinical trials related to Pseudomonas Infections. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Centre Hospitalier Régional d'OrléansUpdated: Apr 30, 2026Locations: 48
Eligibility criteria

All patients aged 18 or over and requiring intravenous definite antimicrobial th...

Cystic fibrosis [+5]

Status: Recruiting

Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa

This study looks at how well one antibiotic (monotherapy) works compared to two antibiotics (combination therapy) in treating bone infections caused by Pseudomonas aeruginosa. It includes 300 adult patients who had this type of infection confirmed by lab tests and medical imaging. The goal is to find out if using just one antibiotic is as effective as using two, while also looking at side effects, the need for more surgery, antibiotic resistance, and overall antibiotic use.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Centre Hospitalier de Saint-DenisUpdated: Jul 9, 2025Locations: 1
Eligibility criteria

Adult patients (≥18 years old) [+3]

No isolation of Pseudomonas aeruginosa [+2]

Status: Recruiting

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

Participants needed: 100
Trial details
Age: 18-90Biological sex: AllType: ObservationalSponsor: University of UlmUpdated: Jan 17, 2024Locations: 1
Eligibility criteria

age > 18 years [+2]

life expectancy < 24 hours [+1]